Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

CRANBURY, N.J., Feb. 16, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011. In addition, the Company announced that it will present encouraging data from its preclinical studies evaluating the co-administration of pharmacological chaperones with enzyme replacement therapy (ERT) in Fabry disease, as well as from preclinical studies examining the use of pharmacological chaperones for the treatment of genetically defined subpopulations of Parkinson's disease and Alzheimer's disease.

Preliminary Data Update from Phase 2 Long-Term Extension Study of Migalastat HCl for Fabry DiseaseTwenty-six subjects completed either 12 or 24 weeks of treatment with migalastat HCl during the initial Phase 2 studies and 23 subjects enrolled in a separate, long-term extension study designed to evaluate the long-term safety and efficacy of migalastat HCl. Over the course of the initial Phase 2 and extension studies, 15 subjects have been treated with migalastat HCl for more than 3 years and 7 subjects have been treated with migalastat HCl for more than 4 years. Seventeen subjects continue to receive treatment in the ongoing extension study.

During the course of the extension study, treatment with migalastat HCl has continued to be generally well tolerated, with no drug-related serious adverse events. The most common adverse events have been headache, arthralgia, diarrhea and fatigue.

Renal function continues to be evaluated by two measures in the extension study, estimated glomerular filtration rate (eGFR) and 24-hour urine protein. Preliminary data indicate that eGFR has remained stable out to 3-4 years
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... 2015 According to a new market ... For Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic ... Share, Growth, Trends and Forecast, 2013 – 2019,”the global ... in 2012 and is expected to reach USD 28,694.1 ... from 2013 to 2019. , Demand for food ...
(Date:2/26/2015)... Regis Technologies announced new potent compound ... substances. , Regis Technologies is proud to announce the ... Suite (PCS) for 2015. , Regis is a contract ... in Morton Grove, Illinois. The PCS addition will provide ... to about one kilogram per batch. , Regis’ ...
(Date:2/26/2015)... Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the ... the natural wellness sector and in developing a proprietary ... will be featured at the SEC Compliance sponsor booth ... Annual Growth Stock Conference on March 8-11 th ... Drive, Dana Point , California.  One ...
Breaking Biology Technology:One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4
... 1 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... shares of Genmab A/S which stock is traded on ... on February 1,2008. Medarex expects to receive approximately $151.8 ... of Genmab shares reduces Medarex,s,ownership in Genmab to approximately ...
... SAN FRANCISCO, Calif., Jan. 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... offering of 5,000,000 shares of common stock at a ... being offered by Rigel. The underwriters,have an option to ... if any. The offering is expected to close on ...
... , - ENDORSE Global Findings Highlight the ... Management: Systematically Assess,Patient Risk for VTE and Provide ... study (Epidemiologic International Day for the,Evaluation of Patients ... Care Setting) published today in the LANCET(1) demonstrates ...
Cached Biology Technology:Rigel Announces Pricing of Public Offering of Common Stock 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 4
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... Cancer is not a static disease but during its ... adapting to new environmental circumstances, protecting against chemotherapy and ... Until now little was known about the mechanisms involved ... a particularly intriguing way in which a tumour that ...
... at the University of California, Davis, have demonstrated that forest ... rocks, boosting the trees, growth and their ability to pull ... dioxide is the most important climate-change gas, the nitrogen in ... in the future, the researchers say. They report their findings ...
... Sept 1, 2011) Lincoln Park Zoo applauds the federal government,s ... chimpanzees living in the United States as an endangered species. ... conservation of the species, which is endangered in the wild. ... Nature, wild chimpanzees are severely endangered and could become extinct ...
Cached Biology News:Why cancer cells change their appearance? 2Bedrock nitrogen may help forests buffer climate change, study finds 2Bedrock nitrogen may help forests buffer climate change, study finds 3Lincoln Park Zoo applauds government decision to consider reclassifying chimpanzees as endangered 2
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
... qualitatively detect EGFR gene ... (FFPE) tissue sections, metaphase ... preparations, using Chromogenic In ... In Situ Hybridization (FISH) ...
Request Info...
Biology Products: